IRCT20160528028120N1 IRCT 2018-01-19 Isfahan university of medical sciences; research assistant part Symbiotic and blood uremic toxins in hemodialysis patients Gasttro-Resistant Capsules of synbiotic Reduced blood uremic toxins in hemodialysis patients: double-blind placebo-controlled randomized clinical trial. 2016-06-01 anticipated 46 Complete https://irct.ir/trial/22881 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Dual block Subjects will randomly allocated to block 1 and block 2 with the use of stratif block randomization according to gender, age (± 5 years) and hemodialysis duration (± 6 months), Blinding description: double-blind To conduct the study in a double-blinded nature, the placebo and synbiotic capsules will encode as A and B, respectively, by a third person and patients and investigators will blind about the arms of the study. 2 end stage renal disease. Intervention 1: synbiotic The synbiotic capsules (GeriLact brand; ZIST TAKHMIR Company, Tehran; Iran) contained Lactobacillus casei (3.5×109CFU), Lactobacillus acidophilus (1.5×109CFU), Lactobacillus rhamnosus (3×109CFU), Lactobacillus bulgaricus (3.5×108CFU), Bifidobacterium breve (5×109CFU), Bifidobacterium longum (1×1010CFU), Streptococcus thermophiles (3.5×108CFU) as probiotic and fructooligosaccharide as prebiotic as well as lactose, magnesium stearate and talc as filling materials.During the 8-week intervention, the synbiotic group will receive 2 synbiotic capsules daily, between the main meals (500 mg per one capsule; onecapsule per time), containing 1000mgsynbiotic. Intervention 2: placebo maltodextrin (2 capsules per day; 1000mg). Yes - There is a plan to make this available What will be shared: all data except personal data When: 2 year after pablication To whom: academic researcher Conditions: honest Where to obtain: soheila.mirzaeian@yahoo.com How to obtain: one week after request Comments: